Advertisement
Canada markets open in 4 hours 15 minutes
  • S&P/TSX

    22,259.16
    -31.46 (-0.14%)
     
  • S&P 500

    5,187.67
    -0.03 (-0.00%)
     
  • DOW

    39,056.39
    +172.13 (+0.44%)
     
  • CAD/USD

    0.7283
    -0.0005 (-0.07%)
     
  • CRUDE OIL

    79.77
    +0.78 (+0.99%)
     
  • Bitcoin CAD

    84,047.92
    -1,529.48 (-1.79%)
     
  • CMC Crypto 200

    1,322.19
    +22.09 (+1.70%)
     
  • GOLD FUTURES

    2,318.00
    -4.30 (-0.19%)
     
  • RUSSELL 2000

    2,055.14
    -9.51 (-0.46%)
     
  • 10-Yr Bond

    4.4920
    +0.0290 (+0.65%)
     
  • NASDAQ futures

    18,125.50
    -61.00 (-0.34%)
     
  • VOLATILITY

    13.24
    +0.24 (+1.85%)
     
  • FTSE

    8,362.10
    +8.05 (+0.10%)
     
  • NIKKEI 225

    38,073.98
    -128.39 (-0.34%)
     
  • CAD/EUR

    0.6786
    +0.0010 (+0.15%)
     

Stereotaxis to Present at Cowen 43rd Annual Health Care Conference

Stereotaxis, Inc.
Stereotaxis, Inc.

ST. LOUIS, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in the Cowen 43rd Annual Health Care Conference.

Mr. Fischel will present on Stereotaxis’ business and technology during a Fireside Discussion with Josh Jennings, Cowen’s Managing Director & Senior Research Analyst, on Monday, March 6, 2023, at 11:10 am ET. Mr. Fischel will be available for one-on-one meetings the remainder of the day.

“We look forward to joining Cowen and sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with investors,” says Mr. Fischel.

ADVERTISEMENT

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com